Diana Cirstea

4.4k citations

80 papers · 2.4k indexed · 1 hit paper · h-index 22

Co-authors: Noopur Raje Teru Hideshima Kenneth C. Anderson Nikhil C. Munshi Güllü Görgün Loredana Santo Homare Eda Paul G. Richardson
Topics: Multiple Myeloma Research and Treatments (60 papers)Protein Degradation and Inhibitors (21 papers)Peptidase Inhibition and Analysis (15 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: Journal of Clinical Oncology Blood PLoS ONE
Partner nations: United States Japan United Kingdom

In The Last Decade

Diana Cirstea

78 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

2012 488 citations Loredana Santo, Teru Hideshima et al. Blood profile →

Peers

Countries citing papers authored by Diana Cirstea

Since Specialization

Citations

This map shows the geographic impact of Diana Cirstea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Cirstea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Cirstea more than expected).

Fields of papers citing papers by Diana Cirstea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Cirstea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Cirstea. The network helps show where Diana Cirstea may publish in the future.

Co-authorship network of co-authors of Diana Cirstea

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Cirstea. A scholar is included among the top collaborators of Diana Cirstea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Cirstea. Diana Cirstea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma 2025 ·Blood Advances ·Joshua Gustine,Andrew R. Branagan,Diana Cirstea,(unknown),(unknown),Andrew J. Yee,Marcela V. Maus,Matthew J. Frigault,Noopur Raje	1
2	Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury 2025 ·Blood Advances ·(unknown),(unknown),(unknown),Samuel Han,(unknown),Andrew R. Branagan,Elizabeth O’Donnell,Diana Cirstea,Noopur Raje,Andrew J. Yee	2
3	Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy 2025 ·Blood Advances ·Jessica S Little,(unknown),(unknown),Andrew J. Yee,Omar Nadeem,Shonali Midha,Adam S. Sperling,(unknown),Noopur Raje,Matthew J. Frigault,Diana Cirstea,Sarah P. Hammond	1
4	Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma 2025 ·Ruth Choa,Kevin C. Miller,(unknown),(unknown),Samuel Han,(unknown),Andrew J. Yee,Andrew R. Branagan,(unknown),Matthew J. Frigault,Noopur Raje,Diana Cirstea	0
5	Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels 2025 ·Blood Advances ·Rahul Banerjee,Meera Mohan,Kai Rejeski,(unknown),Diana Cirstea,Gurbakhash Kaur,Shonali Midha,Georgia McCaughan,(unknown),Nikita Mehra,Bhausaheb Bagal,Noopur Raje	2
6	Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma 2024 ·Blood Cancer Journal ·Rie Nakamoto-Matsubara,Valentina Nardi,Nora Horick,Tsuyoshi Fukushima,(unknown),(unknown),Kiyosumi Ochi,Cristina Panaroni,Keertik Fulzele,(unknown),Andrew R. Branagan,Diana Cirstea,Andrew J. Yee,David T. Scadden,Noopur Raje	2
7	OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Joshua Gustine,Andrew R. Branagan,Diana Cirstea,(unknown),(unknown),Andrew J. Yee,Matthew J. Frigault,Noopur Raje	1
8	Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis. 2024 ·Journal of Clinical Oncology ·(unknown),(unknown),(unknown),Andrew R. Branagan,Diana Cirstea,(unknown),(unknown),Noopur Raje,Andrew J. Yee	1
9	Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial 2024 ·The Lancet Haematology ·Elizabeth O’Donnell,Clifton C. Mo,Andrew J. Yee,Omar Nadeem,Jacob P. Laubach,Jacalyn Rosenblatt,Nikhil C. Munshi,Shonali Midha,Diana Cirstea,(unknown),Nora Horick,Paul G. Richardson,Noopur Raje	8
10	A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) 2023 ·Blood ·Elizabeth O’Donnell,Clifton C. Mo,Andrew J. Yee,Omar Nadeem,Andrew R. Branagan,Jacob P. Laubach,Jacalyn Rosenblatt,Nora Horick,Paul G. Richardson,Noopur Raje,Diana Cirstea	2
11	Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma 2021 ·JNCI Journal of the National Cancer Institute ·Nathanael R. Fillmore,Clark DuMontier,(unknown),Jennifer La,Mara M. Epstein,David Cheng,Diana Cirstea,Sarvari V. Yellapragada,Gregory A. Abel,J. Michael Gaziano,Nhan Do,Mary T. Brophy,Dae Hyun Kim,Nikhil C. Munshi,Jane A. Driver	11
12	Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells 2015 ·PLoS ONE ·Rikio Suzuki,Shohei Kikuchi,Takeshi Harada,Naoya Mimura,Jiro Minami,Hiroto Ohguchi,Yasuhiro Yoshida,M. Sagawa,Güllü Görgün,Diana Cirstea,Francesca Cottini,Jana Jakubı́ková,(unknown),Dharminder Chauhan,Paul G. Richardson,Nikhil C. Munshi,Kiyoshi Ando,Teruhiro Utsugi,Teru Hideshima,Kenneth C. Anderson	19
13	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma 2014 ·Molecular Cancer Therapeutics ·Diana Cirstea,Loredana Santo,Teru Hideshima,Homare Eda,Yuko Mishima,Neeharika Nemani,Anuj Mahindra,Andrew J. Yee,Güllü Görgün,Yiguo Hu,Hiroto Ohguchi,Rikio Suzuki,Francesca Cottini,Sylvie M. Guichard,Kenneth C. Anderson,Noopur Raje	24
14	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition 2014 ·Cancer Research ·Naoya Mimura,Teru Hideshima,Toshiyasu Shimomura,Rikio Suzuki,Hiroto Ohguchi,(unknown),Shohei Kikuchi,Yasuhiro Yoshida,Francesca Cottini,Jana Jakubı́ková,Diana Cirstea,Güllü Görgün,Jiro Minami,Yu‐Tzu Tai,Paul G. Richardson,Teruhiro Utsugi,Atsushi Iwama,Kenneth C. Anderson	66
15	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs 2013 ·Leukemia ·Diana Cirstea,Teru Hideshima,Loredana Santo,Homare Eda,Yuji Mishima,Neeharika Nemani,Yiguo Hu,Naoya Mimura,Francesca Cottini,Güllü Görgün,Hiroto Ohguchi,Rikio Suzuki,Hannes Loferer,Nikhil C. Munshi,K. C. Anderson,Noopur Raje	47
16	In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 2013 ·Bone ·Samantha Pozzi,Mariateresa Fulciniti,Yan Hua,Sonia Vallet,Homare Eda,Kishan Patel,Loredana Santo,Diana Cirstea,Teru Hideshima,(unknown),Stuart Kuhstoss,Kenneth C. Anderson,Nikhil C. Munshi,David T. Scadden,Henry M. Kronenberg,Noopur Raje	56
17	Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma 2012 ·Clinical Cancer Research ·Claire Fabre,Naoya Mimura,Kathryn Bobb,Sun‐Young Kong,Güllü Görgün,Diana Cirstea,Yiguo Hu,Jiro Minami,Hiroto Ohguchi,Jie Zhang,Jeffrey Meshulam,Ruben D. Carrasco,Yu‐Tzu Tai,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson	66
18	A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function 2011 ·Leukemia ·Sonia Vallet,Samantha Pozzi,Kishan Patel,(unknown),Mariateresa Fulciniti,Petter O. Veiby,Teru Hideshima,Loredana Santo,Diana Cirstea,David T. Scadden,Kenneth C. Anderson,Noopur Raje	126
19	Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma 2010 ·Molecular Cancer Therapeutics ·Diana Cirstea,Teru Hideshima,Scott J. Rodig,Loredana Santo,Samantha Pozzi,Sonia Vallet,Hiroshi Ikeda,Giulia Perrone,Güllü Görgün,Kishan Patel,Neil Desai,Peter Sportelli,Shweta Kapoor,Shireen Vali,Siddhartha Mukherjee,Nikhil C. Munshi,Kenneth C. Anderson,Noopur Raje	136
20	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition 2010 ·Oncogene ·Loredana Santo,Sonia Vallet,Teru Hideshima,Diana Cirstea,Hiroshi Ikeda,Samantha Pozzi,Kishan Patel,Yutaka Okawa,Güllü Görgün,Giulia Perrone,Elisabetta Calabrese,Murray Yule,Matthew Squires,Marco Ladetto,Mario Boccadoro,Paul G. Richardson,Nikhil C. Munshi,K C Anderson,Noopur Raje	114

About Diana Cirstea

Diana Cirstea is a scholar working on Hematology, Oncology and Genetics, having authored 80 papers that have together received 2.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (60 papers), Protein Degradation and Inhibitors (21 papers) and Peptidase Inhibition and Analysis (15 papers). The work is most often cited by research in Hematology (894 citations), Oncology (1.1k citations) and Molecular Biology (1.6k citations). Diana Cirstea has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Noopur Raje, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi, Güllü Görgün, Loredana Santo, Homare Eda, Paul G. Richardson, Yiguo Hu and Sonia Vallet. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact